相关实验视频
Updated: Jun 23, 2025

08:28
Single-molecule Manipulation of G-quadruplexes by Magnetic Tweezers
Published on: September 19, 2017
8.0K
开发一种基于G-四重复稳定和碳酸酶抑制的多向化疗方法
Alessio Nocentini1, Anna Di Porzio2, Alessandro Bonardi1
1NEUROFARBA Department, Pharmaceutical and Nutraceutical Section and Laboratory of Molecular Modeling Cheminformatics & QSAR, University of Florence, Sesto Fiorentino, Florence, Italy.
Journal of enzyme inhibition and medicinal chemistry
|June 21, 2024
概括
新型抗癌化合物向G-四重复结构和人类碳酸无水酶 (hCA) IX和XII. 这些双重作用的配体在体外和癌细胞中表现有前途,为抗瘤提供了一种新的策略.
科学领域:
- 药用化学 医学化学
- 癌症生物学 癌症生物学
- 结构生物学 结构生物学
背景情况:
- G四重复结构是新兴的抗癌点,对于端粒维护和瘤基因表达至关重要.
- 人类碳酸无水酶 (hCAs) IX和XII是经过验证的抗癌标,特别是在缺氧瘤中,促进转移.
- 开发双重向药物为增强抗瘤疗效提供了一个有希望的策略.
研究的目的:
- 设计和合成新型化合物,针对G-四重复结构和HCAs IX/XII.
- 为了评估这些双重作用配体的体外疗效和选择性.
- 阐明连接体和G-四重复结构之间的相互作用机制.
主要方法:
- 与hCA IX/XII抑制部分相关的柏柏林基联体的合成.
- 在实验室测定G-四倍体稳定和hCA IX/XII抑制.
- 一个G-四复合体-连接体复合体的晶体结构的确定.
- 在低氧条件下对癌细胞进行细胞毒性测定.
主要成果:
- 化合物选择性地稳定了G-四重复结构,并抑制了HCAs IX和XII.
- 晶体结构揭示了联体-G-四重复相互作用模式.
- 最强大的配体对缺氧性,CA IX阳性癌细胞表现出显著的细胞毒性.
- 结合体被证明可以稳定瘤细胞内的G-四复合体.
结论:
- 成功开发了一种新型的双重向抗癌化合物.
- 这些化合物具有强大的抗瘤活性,通过同时激活G-四重复合体和hCAs IX/XII.
- 这些发现支持这些连接体作为低氧瘤的新治疗策略的潜力.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Electron Transport Chain: Complex I and II
12.9K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.9K

